【Abmole 推薦】2023年FDA-approved New Agonists/Inhibitors
2023年FDA-approved
新致效劑(Agonists)/抑制劑(Inhibitors)
2023年新藥研發群星閃耀，多款針對不同目標的致效劑(Agonists)、抑制劑(Inhibitors)獲得FDA批准，為生命科學及醫學藥學研究領域提供了更多的陽性對照化合物供選擇。
以下是Abmole目前可提供的新抑制劑/致效劑清單：
| Cat. No. | Product Name | Target | Structural Formulas |
| M20844 | Bexagliflozin | SGLT2 |  |
| M2303 | Capivasertib | pan-AKT |  |
| M8924 | Daprodustat | HIF |  |
| M25574 | Durlobactam | β-lactamase |  |
| M14629 | Elacestrant | ER |  |
| M10226 | Etrasimod | S1PR |  |
| M14021 | Fezolinetant | NK3 |  |
| M7554 | Fruquintinib | VEGFR 1/2/3 |  |
| M40960 | Gepirone | 5-HT1A |  |
| M5688 | Heparin | Others |  |
| M14076 | Iptacopan | Factor B |  |
| M10186 | Leniolisib | PI3K |  |
| M40537 | Lotilaner | GABACls |  |
| M1700 | Momelotinib | JAK1/2 |  |
| M10215 | Motixafortide | CXCR4 |  |
| M10594 | Nirmatrelvir | 3CLPRO |  |
| M9041 | Nirogacestat | γ-secretase |  |
| M10081 | Omaveloxolone | KEAP1/NRF2 |